Effects of aclacinomycin-A on murine leukemia.
Effects of aclacinomycin-A (ACM) on leukemic cells and normal hematopoietic stem cells were studied for the purpose of evaluating the usefulness of this agent as an antileukemic agent. ACM suppressed not only leukemic colony-forming unit (LCFU) in the radiation-induced murine erythroleukemia, but also normal hematopoietic stem cells (CFU-S, CFU-C) in mice. However, LCFU was the most sensitive to ACM. After the administration of ACM at a dose of 5 mg/kg. LCFU was suppressed to 0.02 of the control on day 3 and recovered within 5 days. Splenic CFU-S and CFU-C were suppressed to the nadirs on day 2 and day 1, respectively, and they recovered within 5 days. On the basis of the differences in the sensitivities to ACM and recovery patterns between LCFU and normal hematopoietic stem cells. ACM at a single dose of 5 mg/kg was administered every 3 days (total dose of 25 mg/kg) into leukemic mice, and the increase in mean lifespan obtained 113.9%. Effectiveness of ACM in the treatment of acute leukemia was discussed.
D015250:Aclarubicin; D000818:Animals; D001854:Bone Marrow Cells; D002470:Cell Survival / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D003114:Colony-Forming Units Assay; D005260:Female; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D007942:Leukemia, Experimental / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D013154:Spleen / Q000166:cytology / Q000473:pathology
D009279:Naphthacenes; D015250:Aclarubicin